MedTrace Logo

Imiquimod and Actinic Keratoses: an Observational Study

NCT01151956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 463

Last updated 2010-07-01

No results posted yet for this study

Summary

Objective: To show how dermatologists treat actinic keratoses with imiquimod 5% cream in their daily clinical routine.

Design: Prospective, non-interventional, observational, multicenter clinical study.

Setting: Offices of 93 non hospital based Austrian dermatologists. Participants: Inclusion of the 463 patients into the study was solely based on the treatment decision of the dermatologist and the patients will.

Interventions: No specific interventions except suggested time points of visits with pre-defined documentation forms. The therapy of actinic keratoses followed the imiquimod label (3x/week for 4 weeks, 4 therapy free weeks, another 3x/week for 4 weeks, when needed) Main outcome measure: Information about the typical imiquimod patient, therapeutic course, treatment decisions, safety and satisfaction of patients/dermatologists.

Conditions

  • Actinic Keratosis

Sponsors & Collaborators

  • MEDA Pharma GmbH & Co. KG

    collaborator INDUSTRY

  • Federal University Teaching Hospital, Feldkirch, Austria

    lead OTHER

Principal Investigators

  • Robert Strohal, AssocProfDr · Federal University Teaching Hospital of Feldkirch, Dept. of Dermatology

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Completion
2009-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151956 on ClinicalTrials.gov